preclinical white papers and articles

  1. Navigating The FDA's Draft Guidance On Psychedelic Drug Development 11/2/2023

    Uncover new guidance for the development of innovative therapies in the realm of mental health and addiction treatment.

  2. Psychedelics As Therapeutics – What Developers Need To Know 10/29/2023

    Drug developers and others intrigued by the dynamic and promising field of psychedelics as therapeutics can gain valuable guidance from a recap of the 3rd annual Psychedelic Therapeutic and Drug Development Conference.

  3. The Criticality Of CMO Selection For Small Biopharma Companies 10/29/2023

    Delve into the criteria that small or early-stage biopharma companies should consider during their CMO selection process, along with key considerations to keep in mind.

  4. Raw Materials Control For Biotechs (Part 1) 10/23/2023

    Navigate challenges posed by raw material usage and learn how to lay a robust current Good Manufacturing Practices groundwork for a control program.

  5. Unitary Patents & Their Impact On Life Sciences Companies 6/26/2023

    Learn about the ways Unitary Patents (UP) are working to simplify systems for patent protection in the EU, such as streamlining validation and translation requirements and making the process more cost-effective and less complex.

  6. Navigating Research To Development: Potential Challenges & Pitfalls 6/19/2023

    With many steps between drug discovery and regulatory approval, there are several factors to consider at the earliest stages. Find advice for avoiding major pitfalls during the drug development process.

  7. The Compounding Benefits Of The Right Preclinical Development Approach 6/14/2023

    Traversing the so-called “valley of death” and forging a successful pathway to clinical development hinges on determining the optimal strategy for a product and indication.

  8. Revolutionary CAR-T Therapies Pave Way To Conquer Solid Tumors 5/1/2023

    Get a comprehensive and insightful overview of the latest advancements in CAR-T cell therapy and their potential to transform cancer treatment.

  9. Collaborating To Support Customers From Discovery Through To Clinical 4/12/2023

    The pharmaceutical industry's siloed structure often leads to inefficient and costly development. Charles River and Quotient Sciences' collaboration offers an integrated approach designed to remove obstacles and reduce timelines.

  10. FDA Introduces 'Nonclinical Tests' Term, Signaling A New Beginning 3/27/2023

    Discover how this terminology change will require the investment of time and resources to deliver its full potential.